Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making strides in both clinical and commercial arenas, as detailed in a recent BioMedWire Podcast featuring Executive Co-Chairman and Co-Founder Anthony Durkacz. The company is advancing Lucid-MS, its lead drug candidate for multiple sclerosis, toward human trials while simultaneously capitalizing on the commercial potential of unbuzzd, a product designed to accelerate alcohol metabolism.
Durkacz highlighted that Lucid-MS aims to address mobility damage associated with MS, a debilitating neurodegenerative disease. The company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the first administration of the candidate to human MS patients. This step is critical for validating Lucid-MS's potential to prevent and reverse myelin degradation, as demonstrated in preclinical models. The full podcast can be accessed at https://ibn.fm/IWnPQ.
In addition to its clinical pipeline, Quantum BioPharma is leveraging its commercial product unbuzzd, which is already available over the counter. The company spun out the OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and a royalty agreement: 7% of sales until payments total $250 million, thereafter dropping to 3% in perpetuity. Durkacz emphasized that unbuzzd represents a strategic revenue stream that supports the company's broader mission.
Quantum BioPharma's dual strategy—combining pharmaceutical development with commercial products—positions it to address neurodegenerative, metabolic, and alcohol-misuse conditions. The company retains full rights to develop pharmaceutical formulations of unbuzzd, ensuring long-term value. For ongoing updates, visit the company's newsroom at https://ibn.fm/QNTM.
This announcement underscores the importance of Quantum BioPharma's approach: advancing a promising MS therapy while generating revenue from a commercially available product. The Phase 2 trial for Lucid-MS could be a pivotal milestone, potentially offering new hope for MS patients suffering from mobility issues. Meanwhile, unbuzzd's market traction provides financial stability and validates the company's innovation in metabolic health.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Investors are cautioned not to place undue reliance on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
